April 9, 2020 | Cannabis Law Report
Israel’s largest manufacturer and home-delivery distributor of medical cannabis products, Panaxia Labs Israel Ltd. (TASE: PNAX), announced a contractual agreement to use a Maltese R&D facility for expanding its offerings to the European market.
The news comes on the heels of Panaxia’s recent announcement of a share offering with the proceeds expected to go toward European expansion.
According to the agreement, Panaxia is authorized to employ the research and development of the holder of controlling interest in Malta for manufacturing several hundred thousand medical cannabis products such as oils, inhalers, sublingual tablets and suppositories, annually.
Read More On: Cannabis Law Report Website